Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,428 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: opiates Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users

NCT01825447
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Oxycodone + Naltrexone, Oxycodone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension.

NCT00315458
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 30, 2026, 7:16 PM EDT
Withdrawn Phase 4 Interventional

A Comparison of Exparel Local Anesthetic in Total Knee Arthroplasty (TKA) Patients

NCT02765815
View directory record Official record
Conditions
Osteoarthritis, Knee, Arthroplasty, Replacement, Knee
Interventions
Liposomal bupivacaine, 266mg, Bupivacaine 0.5 % with Epinephrine, Ketorolac 30mg, Morphine 10mg, Bupivacaine 0.25% with Epinephrine
Drug
Lead sponsor
Holy Cross Hospital, Florida
Other
Eligibility
18 Years to 88 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Active, not recruiting Not applicable Interventional

Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care

NCT06810076
View directory record Official record
Conditions
Opiate Overdose, Opioid-Related Disorders, Narcotic-Related Disorders, Substance-related Disorders, Chemically-Induced Disorders, Mental Disorders
Interventions
Machine Learning-Based Clinical Decision Support: Overdose Prevention Alert (OPA) Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 4 Interventional Results available

Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings

NCT02978417
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Naltrexone for extended-release injectable suspension, Oral naltrexone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Herb-Opioid Interactions

NCT00027014
View directory record Official record
Conditions
Pain
Interventions
St. John's Wort, oxycodone, fentanyl
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2007 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Phase 2 Interventional Results available

Low-dose Naltrexone for Bladder Pain Syndrome

NCT04450316
View directory record Official record
Conditions
Bladder Pain Syndrome, Interstitial Cystitis
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Not listed Phase 1 Interventional

Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence

NCT02052258
View directory record Official record
Conditions
Opiate Dependence
Interventions
Oxytocin
Drug
Lead sponsor
MacDonald, Kai, M.D.
Individual
Eligibility
18 Years and older · Male only
Timeline
Started 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age

NCT01508455
View directory record Official record
Conditions
Anesthesia
Interventions
Dexmedetomidine, Midazolam, Fentanyl, Morphine
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
28 Weeks to 36 Weeks
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Louisville, Kentucky • Pittsburgh, Pennsylvania • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers Results available

Opioid-Free Pain Protocol After Shoulder Arthroplasty

NCT05488847
View directory record Official record
Conditions
Shoulder Arthropathy, Shoulder Pain
Interventions
Celecoxib, Pregabalin, Tramadol, Dexamethasone, Acetaminophen, Ropivicaine, Epinephrine, Ketorolac, Tizanidine, Magnesium, Ibuprofen, Oxycodone Hydrochloride 5 Mg
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed No phase listed Observational

Precision Opioid Care After Cesarean Delivery (PRECISE-CD)

NCT05280743
View directory record Official record
Conditions
Cesarean Section Complications, Opioid Use
Interventions
Oxycodone
Drug
Lead sponsor
Grace Lim, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
341 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 30, 2026, 7:16 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Ketorolac vs Oxycodone for Great Toe Arthrodesis

NCT05054868
View directory record Official record
Conditions
Arthrodesis
Interventions
Oxycodone, Ketorolac
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

NCT00877591
View directory record Official record
Conditions
Opioid Dependency, HIV Infections
Interventions
Fosamprenavir/Ritonavir, Darunavir/Ritonavir, Rifampin, Rifabutin, Buprenorphine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 30, 2026, 7:16 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Impact of Prophylactic Ephedrine on Fetal Heart Tracing and Uterine Tetanic Contraction After CSE

NCT05873218
View directory record Official record
Conditions
Labor
Interventions
Ephedrine, Normal Saline Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA

NCT02601027
View directory record Official record
Conditions
Breast - Female
Interventions
Transversus Abdominis Plane (TAP) block, Nimbus Infusion Pump IV Administration, Bupivacaine infusion, Acetominophen, Hydromorphone, Oxycodone, Ondansetron
Procedure · Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 1Phase 2 Interventional

CBT4CBT for Office Based Buprenorphine

NCT03580902
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CBT4CBT-Buprenorphine, Buprenorphine/naloxone
Behavioral · Drug
Lead sponsor
CBT4CBT, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 30, 2026, 7:16 PM EDT
Recruiting Phase 1 Interventional

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

NCT05136846
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Carboplatin, Durvalumab, Paclitaxel, Papaverine, Radiation Therapy, Pemetrexed, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging of the Brain with and without Contrast, Biospecimen Collection
Drug · Biological · Radiation + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Duarte, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 7:16 PM EDT
Completed No phase listed Observational

PG and PK of Oxycodone to Personalize Post-op Pain Management Following Surgery in Children

NCT03495388
View directory record Official record
Conditions
Postoperative Pain, Opioid Dependence
Interventions
Oxycodone
Drug
Lead sponsor
Senthil Sadhasivam
Other
Eligibility
8 Years to 18 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 1 Interventional

Buprenorphine and Naloxone Combination Study - 10

NCT00015288
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

NCT01367561
View directory record Official record
Conditions
Healthy Males
Interventions
Naloxone, IV Methylnaltrexone (MNTX), Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 30, 2026, 7:16 PM EDT
Terminated Phase 4 Interventional Results available

Trial of Analgesia With Lidocaine or Extended-release Oxycodone for Neuropathic Pain Treatment in Multiple Sclerosis

NCT00414453
View directory record Official record
Conditions
Neuropathic Pain, Chronic Pain, Multiple Sclerosis
Interventions
Lidocaine patch 5%, Extended-release oxycodone, Placebo extended-release oxycodone pills, Placebo lidocaine patches
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Phase 2 Interventional

A Laboratory Model for Heroin Abuse Medications - 8

NCT00000273
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
Interventions
opiates
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Not listed Phase 4 Interventional

Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery

NCT02958566
View directory record Official record
Conditions
Colon Cancer, Colon Diverticulosis, Colonic Neoplasms, Colonic Diverticulitis, Pain, Postoperative, Ileus, Ileus Paralytic, Ileus; Mechanical, Constipation Drug Induced, Constipation, Rectum Cancer, Rectum Neoplasm
Interventions
Acetaminophen, Gabapentin, Orphenadrine, Lidocaine, Marcaine, Ketamine, Methadone, Tramadol, Ketorolac, Morphine Sulfate, Fentanyl, Dilaudid, Hydrocodone-Acetaminophen Tab 5-325 MG, HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
Drug
Lead sponsor
University of Illinois College of Medicine at Peoria
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 30, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT01143766
View directory record Official record
Conditions
Conscious Sedation
Interventions
Gabapentin, Standard sedation regimen
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 7:16 PM EDT